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ABSTRACT
Adherence to therapy is defined as the extent to
which a person’s behavior in taking medication,
following a diet, and/or executing lifestyle
changes, corresponds with agreed
recommendations from a healthcare provider.
Patients presenting with type 2 diabetes
mellitus are initially encouraged to maintain a
healthy diet and exercise regimen, followed by
early medication that generally includes one or
more oral hypoglycemic agents and later may
include an injectable treatment. To prevent the
complications associated with type 2 diabetes,
therapy frequently also includes medications
for control of blood pressure, dyslipidemia and
other disorders, since patients often have more
than three or four chronic conditions. Despite
the benefits of therapy, studies have indicated
that recommended glycemic goals are achieved
by less than 50% of patients, which may be
associated with decreased adherence to
therapies. As a result, hyperglycemia and long-
term complications increase morbidity and
premature mortality, and lead to increased
costs to health services. Reasons for
nonadherence are multifactorial and difficult
to identify. They include age, information,
perception and duration of disease, complexity
of dosing regimen, polytherapy, psychological
factors, safety, tolerability and cost. Various
measures to increase patient satisfaction and
increase adherence in type 2 diabetes have been
investigated. These include reducing the
complexity of therapy by fixed-dose
combination pills and less frequent dosing
regimens, using medications that are
associated with fewer adverse events
(hypoglycemia or weight gain), educational
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initiatives with improved patient–healthcare
provider communication, reminder systems
and social support to help reduce costs. In the
current narrative review, factors that influence
adherence to different therapies for type 2
diabetes are discussed, along with outcomes of
poor adherence, the economic impact of
nonadherence, and strategies aimed at
improving adherence.
Keywords: Adherence; Dosing complexity;
Glycemic control; Primary care; Type 2 diabetes
INTRODUCTION
The prevalence of type 2 diabetes mellitus is
increasing globally and has become a major
public health problem. In the USA, a study of
17,306 people over 20 years of age showed that
those diagnosed with diabetes increased
significantly from 6.5% in the 1999–2002
period to 7.8% in 2003–2006 [1]. In 2011, 366
million people worldwide had diabetes and it is
predicted that by 2030, this figure will be 552
million [2]. Diabetes is currently among the top
five causes of death in most high-income
countries and resulted in 4.6 million deaths
globally in 2011. The majority of cases of
diabetes mellitus are type 2, and the greatest
numbers of people with this disease are aged
from 40 to 59 years [2].
The increase in type 2 diabetes is associated
with obesity, hypertension, and an increasingly
elderly population. Over the last 18 years in the
USA, the proportion of adults in the age group
40–74 years with a body mass index C30 kg/m2
has increased from 28% to 36%, while the
proportion undergoing physical activity 12
times a month or more has decreased from
53% to 43%, exacerbating the obesity problem
[3]. However, despite strong clinical
recommendations for individuals with a
history of diabetes to adopt a healthier
lifestyle, adherence to improved diet and
exercise is poor [3]. Although type 2 diabetes
usually occurs in people over the age of
40 years, it is becoming increasingly common
in children, adolescents and young adults due
to reduced physical activity and unhealthy
eating patterns, leading to obesity [4].
The majority of patients with type 2 diabetes
fail to control glycemia with diet and exercise
and require pharmacotherapy—in general,
initially monotherapy with an oral
hypoglycemic agents (OHA); however, owing
to the progressive nature of the disease, most of
the patients will eventually require
combination therapy and ultimately injectable
treatments as monotherapy or part of
polytherapy. Glycemic control in type 2
diabetes is essential to prevent long-term
micro- and macrovascular complications [5]. A
number of factors other than glycated
hemoglobin (HbA1c) level will influence
treatment regimens, and practice guidelines
emphasize the need for concomitant
treatment of other cardiovascular risk factors,
such as arterial hypertension (C140/80 mmHg)
and dyslipidemia [low density lipoprotein (LDL)
[2.6 mmol/L; triglycerides[1.7 mmol/L] [5]. As
a consequence, many patients with type 2
diabetes are taking a complex regimen of
drugs [6].
Drugs and lifestyle changes to control type 2
diabetes and associated conditions can only be
effective through adherence to the overall
prescribed regimen. The World Health
Organization (WHO) has shown that
adherence to long-term therapy for chronic
illnesses in developed countries averages only
around 50% [7]. Adherence rates are usually
reduced for patients with chronic conditions
than those with acute conditions; this is
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associated with the long-term nature of chronic
diseases because the decline in adherence is
most rapid after the first 6 months of therapy [8].
Such reduced adherence not only results in poor
health outcomes but it also has a significant
impact on healthcare costs [7]. Thus, the overall
management of type 2 diabetes should address
adherence as well as appropriate medications.
MATERIALS AND METHODS
The current narrative review examined factors
that influence adherence to various therapies
for type 2 diabetes, the outcomes of poor
adherence, the economic impact of
nonadherence, and strategies designed to
improve adherence. A literature search using
PubMed was performed using the key terms of
‘‘type 2 diabetes’’, and ‘‘adherence’’ or
‘‘compliance’’ or ‘‘persistence’’. The search
included publications regarding clinical trials,
and epidemiology and evidence reviews, in
English or Spanish, with no restriction on dates.
Definitions
Adherence, compliance and persistence are
terms used to define the extent to which a
patient conforms to the prescribed medication,
and are factors that have a major impact on the
outcomes of treatment. Although there has been
a lack of uniformity in definitions describing the
use of prescribed drugs, some attempts have
been made to clearly define these terms [7–9].
Adherence and Compliance
Adherence, as used in chronic disorders, was
defined by the WHO as the extent to which a
person’s behavior with respect to taking
medication, following a diet, and/or executing
lifestyle changes, corresponds with agreed
recommendations from a healthcare provider
[7]. Methods of measuring adherence can be
either direct (biological marker), which is more
sensitive but can be invasive and is not
usually practical, or indirect (self-reporting,
questionnaires, pill counts) [10]. Indirect
methods are frequently used, but can lead to
inaccuracies since patients are often not a
reliable source of information. Electronic
pharmacy data are now readily available and
more recently this indirect method has been
widely used to assess adherence. There are two
common measures of adherence using such
data: the medication possession ratio (MPR;
days of medication collected as a proportion of
days of medication prescribed over a particular
period) and the proportion of days covered
within a given time period. These measures
correlate with the quantity of doses prescribed,
but not their actual administration or timing
[11]. Adherence is usually regarded as the
proportion of patients taking at least 80% of
their prescribed medication [12], but this cut-off
can be up to 90% in some studies [13]. In
general, most studies have measured adherence
in patients continuing medication, which may
underestimate the health burden of poor
adherence for the newly prescribed drugs.
Electronic medical records have facilitated
more comprehensive assessments of patients
prescribed medication and should increase the
reliability of studies on first-time users (primary)
and improve data on continuing medication
(secondary) [14].
Compliance is a term that is often used
synonymously with adherence and is usually
measured as the administered doses as a
proportion of the prescribed doses over a
period of time [15, 16]. While it differs slightly
from adherence in that it does not require the
patient’s agreement to the recommendations
[7], the terminology used in the present report
is consistent with the quoted reference.
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Persistence
The outcomes of treatment are affected not only
by conformity with day-to-day treatment, but
also by the length of time treatment is
continued during the prescribed duration.
Treatment persistence is usually defined as the
duration of time that a patient continues
treatment as a proportion of the prescribed
duration [9]. It is measured as either the
proportion of patients who remain on
treatment for a specified period or the mean
number of days to treatment discontinuation.
ADHERENCE TO RECOMMENDED
THERAPIES
Despite the extensive therapy options available
for various stages of type 2 diabetes, studies
have indicated that less than 50% of patients
achieve the glycemic goals recommended by
the American Diabetes Association (ADA) and
approximately two-thirds die prematurely of
cardiovascular disease [17]. Although data
from a study in the USA indicated an
increase in the percentage of people with
diagnosed diabetes who achieved glycemic,
cardiovascular and lipid control from 7.0% to
12.2% during the period 1999 to 2006,
adherence was still very low, with considerable
room for improvement [1].
Diet and Exercise
Guidelines from the ADA and the European
Association for the Study of Diabetes (EASD)
stress the importance of diet and exercise in
the treatment of all stages of type 2 diabetes
[18]. Despite evidence for the benefits of
exercise, adherence to long-term exercise
programs can vary between 10% and 80%,
particularly in the long term [19]. There is
evidence that patients often have numerous
cycles of weight loss and relapse before
managing to maintain their weight loss,
suggesting that healthcare professionals
should consistently encourage therapeutic
lifestyle changes [5, 18]. The factors that
influence adherence to exercise include
overuse injuries and lack of motivation [20],
and whether the activity is routinely
monitored [21]. However, in a survey of
attitudes to adherence to diet and exercise,
patients with type 2 diabetes and their diabetes
educators viewed barriers differently [22]. With
regard to diet, patients expressed a dislike for
foods included in meal plans, whereas the
educators considered social influences as more
important barriers. With respect to exercise,
diabetes educators considered a lack of
motivation and physical problems to be the
prominent barriers to adherence, whereas
patients reported barriers to be largely related
to convenience, including factors such as the
weather; however, only about one-quarter of
the patients reported that they had been
provided with an exercise plan [22].
Oral Hypoglycemic Agents
There are numerous reviews indicating the lack
of adherence to treatment with one or more
OHAs. It has been demonstrated that there is
an inverse relationship between taking a
prescribed OHA and HbA1c level, with each
10% increase in OHA adherence associated
with a decrease of 0.1% in HbA1c (P\0.001)
[23]. Nevertheless, in an analysis of 11
retrospective studies between 1966 and 2003,
adherence (defined in some of the studies as
taking 90% of medication) to OHA therapy
ranged from 36% to 93% in patients remaining
on treatment for 6–24 months [24]. Prospective
analyses of adherence using electronic
178 Diabetes Ther (2013) 4:175–194
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monitoring indicated that patients took
61–85% of OHA doses as prescribed. In an
extensive study of electronic records for
various medications in patients with diabetes,
among 8,191 patients prescribed glucose-
lowering therapies, only 39.6% were
persistent after 24 months and 4.0% never
filled their prescription (primary
nonadherence), despite 53% having HbA1c
C7% [14]. Using self-reported compliance, a
prospective assessment of 11,896 patients
treated with one or two OHAs found that
only 46% of cases demonstrated optimal
compliance [25]. In a more recent retrospective
analysis of the health records of 2,741 patients
with type 2 diabetes who had recently initiated
OHA therapy, overall adherence was 81%, with
65% of patients having good adherence (C80%
of medication) [23].
These variations in estimates of adherence
between studies are due to a number of factors,
including methodology for measurement of
adherence, patient populations (socioeconomic
effects) and differences in the cut-off point used
for defining adherence. Data for the majority of
these surveys included only secondary adherence
and hence, the problem is likely to be greater than
indicated if primary nonadherence was included.
In a longitudinal retrospective cohort study that
evaluated early nonadherence in new-user
cohorts using electronic medical record data
from 1992 to 2001, 90% of patients filled their
first prescription for metformin or sulfonylurea
within 30 days [26]. However, there were high
rates of early discontinuation and,after6 months,
only 73% of patients continued therapy.
Insulin
As diabetes progresses, insulin may be initiated
alone or in addition to an OHA; patients may
also be taking therapy for associated
complications. In retrospective insulin studies,
adherence was 62% and 64% for long-term and
new-start insulin users, respectively [24]. In
insulin-naı¨ve patients who were prescribed
insulin, primary nonadherence, assessed from
unfilled prescriptions, was reported for 4.5% of
patients, and an additional 25.5% of patients
never obtained a refill [14, 27].
According to a study of 1,099 patients with
type 2 diabetes who were treated with insulin in
Scotland between 1995 and 2001, the average
adherence to insulin treatment (measured as
the percentage of the number of days per
annum of insulin coverage) was 71% (Fig. 1)
[28]. The level of adherence was a significant
predictor of HbA1c, indicating that improved
adherence resulted in better glycemic control.
In a Spanish study of 294 patients with type 2
diabetes, patients self-assessed their level of
compliance using a questionnaire [29]. The
highest compliance was seen in patients
taking only insulin (67%; Table 1), whereas
the lowest compliance was in patients taking
insulin plus an OHA (39%). Surprisingly, for
patients taking only OHAs, the compliance
level was similar for monotherapy and
combination therapies.
Fig. 1 Number of patients adhering to insulin therapy
(frequency) versus percent of the number of days of drug
adherence per annum for 1,099 patients with type 2
diabetes mellitus in Scotland; reproduced with permission
from Donnelly et al. [28]




Although a beneficial effect of glycemic control
on microvascular and macrovascular
complications has been observed, patients
with type 2 diabetes generally still have an
increased risk for cardiovascular complications.
A meta-analysis of five prospective, randomized,
controlled trials investigating intensive control
of glucose in 33,040 participants with type 2
diabetes showed that 4.5% had non-fatal
myocardial infarction, 7.0% had coronary
heart disease, 3.4% had stroke and 8.8% had
all-cause mortality during approximately
163,000 person-years of follow-up [30]. Non-
fatal myocardial infarction and events
associated with coronary heart disease can be
reduced with intensive glucose-lowering
treatment, but this involves more medications
than conventional treatment [30]. To
counteract the complications associated with
type 2 diabetes, therapy frequently includes
medications for the control of blood pressure
and lipid metabolism. Analysis of data from
840 patients showed that 629 (75%) had high
adherence to antihypertensive monotherapy
and these patients were 45% more likely to
achieve blood pressure control than those with
medium or low compliance [31]. Adherence to
statin therapy to control lipids in 6,462 patients
with diabetes was also reported to be poor, with
a decrease from 87% in the first 3 months to less
than 50% from 6 months onwards [32]. Poor
adherence was significantly correlated with the
occurrence of subsequent coronary heart
disease and stroke.
Electronic data from a study from January to
June 2006 showed that 22.3% of
27,329 patients with diabetes did not become
ongoing users of prescribed cardiometabolic
therapies, a further 6.4% discontinued therapy
and only 39% of the patients were persistent
users at 24 months [14]. Only 33.2% of 6,426
patients prescribed a lipid-lowering therapy
and 41.5% of patients prescribed an
antihypertensive persisted with therapy at
24 months. Secondary assessments in the
study showed that 28.9% of patients had poor
adherence. When patients who were prescribed
a new medication were assessed (primary




There are many potential reasons for
nonadherence to medication and, frequently,
more than one is present for any given patient.
The reasons for medication adherence are
multifactorial and difficult to identify; they
include age, perception and duration of
Table 1 Percent of patients with reported level of treatment adherence by type of pharmacologic treatment; reproduced
with permission from Yurgin et al. [29]
All treatments Oral therapy Insulin therapy
Monotherapy Combination Monotherapy Combination Plus OHA
High compliance 50 49 50 67 57 39
Moderate compliance 41 41 42 29 29 47
Low compliance 9 10 8 4 14 14
OHA oral hypoglycemic agent
180 Diabetes Ther (2013) 4:175–194
123
disease, polytherapy, psychological factors,
safety, tolerability, and cost. Some of these
factors cannot be altered, although others are
amenable to modification.
Complexity of Dosing Regimens
The chronic progressive nature of type 2
diabetes means that once started, patients will
not only take medication for life, but the
complexity of the medication regimen is likely
to increase over time. Over the last two decades,
as understanding of the disease has increased
steadily, there has been an increased complexity
in the therapy administered. According to an
assessment carried out in the USA, where the
number of prescriptions issued between 1991
and 2000 was measured, the number of patients
who had at least five prescriptions increased
from 18.2% to 29.9% (P\0.001) [6]. Indeed,
multifactorial medication for diabetes and
related complications can involve up to 10
tablets per day [33], and there is no doubt that
the complexity of treatments has a profound
influence on adherence [34]. For example, in a
study of patients starting bisphosphonates for
osteoporosis, an increasing burden of
comorbidities, including diabetes, was shown
to be associated with decreased compliance
with medications [35].
In general, patients with type 2 diabetes
begin pharmacotherapy with metformin, but
progress to more than one prescribed OHA to
maintain glycemic control [5, 18]. There have
been a number of studies of compliance with
OHAs and the majority indicate that
adherence declines as the number of drugs
increases [36]. Because type 2 diabetes is
progressive, and oral therapies fail to control
HbA1c over time, most patients will eventually
resort to injectable regimens and adherence to
these is low [37].
Safety and Tolerability
Nonadherence could also be due to adverse
events associated with medications. The
majority of patients with type 2 diabetes are
overweight or obese at diagnosis, and some of
the current therapeutic options are associated
with weight gain and hypoglycemia. In a
retrospective study of 294 patients, obese or
severely obese patients were 2.2 times more
likely to have low or moderate compliance
compared with non-obese patients [95%
confidence interval (CI) 1.31–3.74; P = 0.002]
[38]. From a meta-analysis of five studies, it
was concluded that intensive treatment of
type 2 diabetes, where targets for HbA1c are
lower, can significantly reduce HbA1c level
compared with conventional treatment, and
may be associated with a reduction of
cardiovascular events and myocardial
infarction [39]. However, recent results from
large clinical trials have indicated that
intensive glucose control does not reduce
macrovascular disease in older patients with
long-standing diabetes [40] and may be
associated with increased mortality [41].
Intensive treatment has also resulted in a
higher body mass index and an increased
incidence of severe hypoglycemia [39, 41].
Medication-related weight gain and increased
cardiovascular risk associated with intensive
treatment are significant predictors of
medication nonadherence [42].
Other less serious side effects, such as
gastrointestinal problems, may also affect
adherence. Extended-release metformin was
associated with significantly less
gastrointestinal events than immediate-release
metformin, and adherence was significantly
greater in patients who used the extended-
release formulation than in those who took
the immediate-release medication [43].
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It is important to take into account such
tolerability issues when considering long-term
therapy. In a survey of data from 2,074 patients
with type 2 diabetes taking more than one
OHA, but not insulin, between 2006 and
2008 in the USA, the majority (71.7%)
had experienced at least one tolerability
issue (hypoglycemia, constipation/diarrhea,
headaches, weight gain and water retention)
in the prior 2 weeks and 49.7% had experienced
more than two issues [44]. The association
between the number of tolerability issues and
the likelihood of nonadherence was significant
(r = 0.20, P\0.01) and each additional
tolerability issue was associated with 28%
greater probability of nonadherence.
Perceptions of Medication
The perception of efficacy in terms of treatment
can also have a significant effect on adherence.
In a study of 49 patients with type 1 and 108
patients with type 2 diabetes, perceptions of
glycemic control and prevention of
cardiovascular complications were associated
with adherence to insulin, lipid-lowering and
antihypertensive medications, as well as
exercise and diet [45]. The authors concluded
that patients hold specific mental models about
diabetes treatments, which are associated with
adherence. In a study of statin treatment in
patients with diabetes, adherence was worst in
those who considered themselves at lowest risk
for cardiovascular disease at the start [32]. An
exploratory survey among 121 patients with
type 2 diabetes showed that 32.8% thought
medication would cause unpleasant side effects
and 13.9% thought it would lead to weight
gain, and these factors were associated with
reduced medication adherence [46].
There is considerable resistance among
patients to the initiation of injection regimens.
In the Diabetes Attitudes, Wishes and Needs
(DAWN) study, 48% of insulin-naı¨ve patients
with type 2 diabetes perceived insulin initiation
as a failure to adequately manage their disease
[47]. Efficacy of insulin was perceived to be low
and only about one-fifth of the patients and
one-half of the physicians believed that insulin
would improve management of the diabetes.
Psychological insulin resistance was seen in
another study of insulin-naı¨ve patients [48].
Patients unwilling to accept insulin reported an
objection to lifelong insulin use and, compared
with patients willing to accept insulin, were
more likely to see its use as due to their failure to
control the disease. In patients newly prescribed
with insulin, 35% who were nonadherent
believed that insulin caused harm and
frequently felt that the risks and benefits of
insulin had not been adequately explained [27].
The most common reasons given for failing to
initiate insulin were plans to change health
behavior (25%), injection phobia (13%),
negative impact on work (9%), concerns about
long-term medication use (9%), inconvenience
(6%), and not believing insulin was necessary
(6%). In a prospective self-report survey of
100 adult insulin-naı¨ve patients with type 2
diabetes, 33% were unwilling to take insulin
due to concerns regarding hypoglycemia, the
permanent need for insulin therapy, less
flexibility and feelings of failure [49].
Economic Considerations
In lower-income groups, the cost of
medications can be a reason for a lack of
adherence. A cross-sectional analysis of
baseline information from 77 patients in a
randomized, controlled diabetes intervention
study in the USA showed that 34% of patients
stated that paying for medications was a reason
for the lack of adherence [50]. In a study in
182 Diabetes Ther (2013) 4:175–194
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France, a multivariate regression analysis was
used to examine factors associated with
adherence, which were determined from a
patient-reported questionnaire [51]. Poor
adherence was significantly associated with
financial difficulties as well as a number of
social factors such as taking the medications
alone, a need for information, and lack of
family or social support.
There have been many trials of educational
intervention methods involving allied health
professionals, which have resulted in increased
adherence where benefits outweigh the costs
associated with the intervention [52, 53].
However, the effects of such interventions are
inconsistent between studies and more research
of methods to reduce nonadherence and
validate cost effectiveness for diabetes is
required [54].
Patient–Provider Interaction
Interaction between patients with diabetes and
their healthcare providers has also been shown
to have an impact on adherence to medication.
In the French ENTRED study of adherence from
a self-administered questionnaire, good
adherence was significantly associated with
follow-up by a diabetes specialist and a good
relationship between patients and physicians
[51]. A poor relationship between the patient
and provider was reported significantly more
frequently by patients with poor adherence to
medications and glucose monitoring, and was
associated with higher HbA1c levels [55].
In the multinational DAWN study, the
patient relationship with the healthcare
provider and having a diabetes nurse at the
premises were positively correlated with
adherence to both medication and lifestyle
regimens [56]. It was suggested that
communication between patients and
healthcare providers resolved patient distress,
and patients were more informed about
treatment options and decisions, which
improved adherence and glycemic control.
OUTCOMES OF POOR ADHERENCE
Clinical Consequences
The main consequence of poor adherence to
medications for glycemic control is decreased
glycemic control, leading to the known
complications of diabetes, including
microvascular and macrovascular diseases and
altered lipid metabolism [5]. For example, in a
retrospective cohort study of 11,532 patients in
which medication adherence was calculated as
the proportion of days covered for filled
prescriptions of OHAs, antihypertensives and
statins, multivariate analyses showed that
medication nonadherence was associated with
higher HbA1c, blood pressure, and LDL
cholesterol levels [57]. Such changes lead to an
increased risk of morbidity and mortality [17]. In
the above cohort study, the increased risks for all-
cause hospitalization (odds ratio [OR] 1.58; 95%
CI 1.38–1.81; P\0.001) and all-cause mortality
(OR 1.81; 95% CI 1.46–2.23; P\0.001) were
significant (Table 2) [57]. In a study of
15,984 patients with insulin-treated type 2
diabetes in the UK, medication noncompliance,
as assessed by the attending physician or nurse
over a 30-month period of observation, was an
independent risk factor for all-cause mortality
(hazard ratio after adjustment for confounding
factors 1.58; 95% CI 1.17–2.14) [58].
Economic Impact
The health-related costs associated with type 2
diabetes morbidity and mortality are
continually increasing and are exacerbated by
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resultant long-term complications. It was
estimated in the USA in 2007 that the direct
and indirect cost of diabetes was $218 billion
per year [59]. The median annual costs for
individuals with diet-controlled type 2 diabetes
who had no other complications were estimated
to be $1,700 for men and $2,100 for women
[60]. Estimates for Spain in 2002 indicated that
the direct healthcare costs for diabetic patients
were €2.4 to €2.7 billion, which corresponded to
between 6.3% and 7.4% of the total national
healthcare system expenditure [61]. Hospital
costs contributed most to the expenditure (€933
million), followed by non-insulin and non-
antihyperglycemic drugs (€777 to €932
million). The costs of insulin and OHAs were
much lower (€311 million), as were primary care
visits (€181 to €272 million), specialized visits
(€127 to €145 million), and disposable elements
(€70 to €81 million) [61].
There have been a number of analyses of the
effect of adherence on costs and, in an analysis
of seven studies, an inverse correlation between
hospitalization costs and adherence was shown
[16]. In a retrospective study of more than
100,000 patients with type 2 diabetes in which
mean adherence to one or more OHAs ranged
from 61.3% to 73.8% during 2 years of follow-
up, annual all-cause healthcare costs were
increased by $336 for nonadherent metformin
users and by $1,509 for nonadherent
sulfonylurea users, compared with adherent
patients [62]. The authors concluded that a
return on investment was possible by increasing
the adherence to antidiabetic therapies.
Using propensity score methods to assess the
effect of adherence on costs, the rate of
hospitalization decreased from 15% to 11.5%
when antidiabetic drug adherence was
increased from 50% to 100% [63]. Increased
adherence resulted in a mean increase in
antidiabetic drug spending of $776 per patient
per year; however, the cost saving for averted
hospitalizations was $886 per patient per year,
providing a cost offset of $1.14 per $1.00 spent.
IMPROVING ADHERENCE
In 2003, the WHO emphasized that ‘‘increasing
the effectiveness of adherence interventions may
have a far greater impact on the health of the
population than any improvement in specific
medical treatments’’ [7]. Until now,
interventions aimed at improving medication
adherence have only been partially successful,
which may in part be due to the multifactorial
Table 2 Association between medication nonadherence and outcomes; adapted with permission from Ho et al. [57]
No. of patients Nonadherent
patients, (%)





All therapy 11,532 21.3 1.81 (1.46–2.23) 1.58 (1.38–1.81)
Oral antihyperglycemics 7,883 20.3 1.39 (1.07–1.82) 1.38 (1.21–1.58)
Antihypertensives 6,217 19.1 1.58 (1.22–2.05) 1.44 (1.24–1.67)
Statins 6,486 24.8 2.07 (1.54–2.80) 1.39 (1.18–1.63)
a Unselected multivariable models were constructed to maximally adjust for confounding, and included sex, age,
comorbidities, medication, blood pressure, low density lipoprotein cholesterol and HbA1c; odds ratios and 95% conﬁdence
intervals were calculated for each independent variable in the multivariable models
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nature of adherence. In addition to reducing
medication complexity, factors such as better
patient information, education and motivation
have been shown in a recent study in Spain to be
associated with improved adherence [64]. Factors
that affect adherence and that are associated with
improvement are summarized in Table 3.
Perceived Improvement
It is probable that patients who achieve
glycemic control with fewer adverse events,
such as weight gain and hypoglycemia, are
more likely to remain adherent to medications.
A number of currently available antidiabetic
medications are effective in lowering glucose
but some, including insulin, sulfonylureas and
thiazolidinediones, are associated with weight
gain and/or hypoglycemia. Some newer
medications, such as dipeptidyl peptidase-4
(DPP-4) inhibitors and glucagon-like peptide-1
(GLP-1) receptor agonists, have improved
records in relation to these side effects. The
observed reduction in weight gain shown by
GLP-1 receptor agonists potentially reduces
adverse cardiovascular outcomes and could
contribute to better adherence [65, 66].
Reducing Complexity
Once a regimen of glucose-lowering
medications has been established, patients are
largely responsible for day-to-day management
of their glycemic control. This normally
involves a daily routine that many patients
have difficulties in following [67, 68].
Modifications might involve decreasing the
number of therapies and frequency of therapy,
and altering the route of administration,
although this is not always straightforward. A
reduction in non-fatal myocardial infarction
and events associated with coronary heart
disease can be achieved with intensive
glucose-lowering treatment, but involves more
medications than conventional treatment [30].
A meta-regression analysis also indicated that
intensive treatment for glycemic and
cardiovascular control significantly reduces the
risk of diabetes-related complications [39],
although such treatment may require three to
ten tablets per day [69]. In the ACCORD trial, an
intensive glucose-lowering treatment was
related to a higher frequency of both minor
and major hypoglycemia compared with
conventional therapy. It was not clear whether
Table 3 Factors that have been shown to reduce adherence and factors associated with improvement in adherence to
medications taken by patients with type 2 diabetes
Factors associated with reduced adherence Factors associated with improved adherence
Polypharmacy, complexity of medication regimens
and injectable medications
Reduced treatment complexity, ﬁxed-dose combinations and
decreased frequency of administration
Associated adverse events, including weight gain
cardiovascular problems and hypoglycemia
Medications that are weight-neutral or weight reducing, and with
glucose-dependent effects, leading to decreased hypoglycemia
Perceptions of efﬁcacy and safety (both patients
and healthcare providers)
Education and increased knowledge
Economic considerations Ensure beneﬁts outweigh costs
Patient–healthcare provider relationship Improved continuity of care, and increased communication
through websites and electronic records
Diabetes Ther (2013) 4:175–194 185
123
the hypoglycemia had an impact on the
increased mortality observed in the intensively
treated group [18].
There is considerable evidence of decreased
adherence related to polytherapy and multiple
daily-dosing schedules in various medical
disorders. For example, an analysis of 76
studies of electronic monitoring showed that
the mean dose-taking compliance declined
significantly (P\0.001) as the number of daily
doses increased (Fig. 2) [70]. Currently, there are
a number of fixed-dose combinations of agents
for the treatment of hyperglycemia in type 2
diabetes, which simplify administration
regimens and increase patient adherence
compared with equivalent combinations of
separate tablets [71].
In a database analysis of 17 studies carried
out between 1998 and 2009, adherence was
reported in 7 studies and was 10–13% higher
for single-tablet, fixed-dose formulations than
loose-dose regimens in patients with type 2
diabetes starting combination therapy [72].
Only one study in that analysis showed no
adherence advantage for combination therapy.
The decrease in adherence was greater in
patients who switched from monotherapy to
loose-dose combination therapy (10%) than in
those who switched to fixed-tablet
combination therapy (1.5%, P\0.001).
Patients on fixed-dose combinations used
fewer healthcare resources, and had decreased
healthcare costs and increased life expectancy
compared with those on loose-dose
combinations [72]. Similar results were
obtained in a review of 11 retrospective
studies where there was a 16% improvement
in adherence in patients converting from
polytherapy to a single combination tablet
[24], and a 12.4% improvement in adherence
was reported in another study of 22,332
patients receiving either fixed-dose
combination therapy or dual therapy [73].
The increased adherence using fixed-dose
combinations is associated with improved
outcomes. A meta-analysis of studies of
therapies for type 2 diabetes showed that
fixed-dose combinations resulted in a
significantly greater decrease in HbA1c than
the equivalent co-administered dual therapies
(pooled mean difference -0.53%, P\0.001),
and there was an associated increase in
adherence, determined by MPR, with the
fixed-dose combination therapy [74]. Data
from a physician-interview study indicated
that the decision to prescribe a fixed-dose
combination was associated with improved
treatment satisfaction among patients [75].
Physicians were less likely to prescribe a fixed-
dose combination as the HbA1c level increased.
However, HbA1c was 0.25% lower for patients
on a fixed-dose combination versus an
equivalent free-form combination, and HbA1c
was 0.42% lower for patients perceived by the






























Fig. 2 Dose-taking compliance by frequency of adminis-
tration per day, using pooled data from published reports
included in Claxton et al. [70]. aOnce daily versus three-
times daily, P = 0.008. bOnce daily versus four-times daily,
P\0.001. cTwice daily versus four-times daily, P\0.001.
Points show mean and standard deviation
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patients perceived by the physician as ‘poorly’
or ‘not at all compliant’; these two factors were
additive, with no interaction, and the authors
suggested that giving a fixed-dose combination
to poorly compliant patients could improve
both compliance and HbA1c level [75].
In patients with type 2 diabetes, the number
of doses required per day has also been shown
to influence adherence. In a review of a
pharmacy claims database, patients on once-
daily regimens had higher adherence (61%)
than those on twice-daily regimens (52%) [76].
A prospective assessment of 11,896 patients
with type 2 diabetes treated with either one or
two OHAs showed that HbA1c level was
positively correlated with daily-dosing
frequency of these agents [25]. Another study
of 4,802 patients found that reducing multiple-
administration treatments from 69.5% to 56.8%
of the patients and increasing once-daily dosing
from 12% to 58.4% led to an increase from 44%
to 69.5% of patients achieving optimal
compliance with therapy after 6 months [77].
Adherence to injectable regimens is lower
than to oral drugs and many patients with
diabetes are reluctant to start injections, despite
the importance of glycemic control. Some of
the barriers to injectable medications can be
overcome by education and counseling, but
resistance and clinical inertia remain a problem
associated with the lifelong nature of the
disease [47, 48]. There have been many
improvements in insulin therapy over the
years that have increased adherence, such as
the use of pen-like devices compared with
conventional syringe and needles. Other
improvements have included the nature of the
insulin preparation. For example, in a study of
modern premixed insulins administered three
times per day to 115 outpatients with type 2
diabetes, mean HbA1c levels, fasting blood
glucose, serum triglycerides and the frequency
of minor hypoglycemic episodes all decreased,
and weight was unchanged, after 2.9 years [78].
The number of non-compliant patients
decreased significantly from 34% to 22%
(P = 0.001) during premixed insulin treatment
versus previous administration of OHA and/or
basal, prandial or separate basal-bolus insulins.
Similar outcomes have been observed in
studies of other chronic diseases. In a general
review of 20 studies published between 1986
and 2007, significantly higher adherence rates
were seen in patients using less frequently dosed
medications (P\0.05) in 15 of the 20 studies
[79]. It is of interest that weekly compared with
daily dosing also increased adherence. In an
analysis of 11 trials, adherence was 8.8–12%
higher for once-weekly dosing than for once-
daily dosing [80]. In the treatment of major
depressive disorder, patient compliance was
better with once-weekly (85.9%) compared
with daily (79.4%) fluoxetine treatment [81],
and similar observations were made with
bisphosphonate treatment for osteoporosis
[82]. Nevertheless, when adherence was poor
not all studies demonstrated improvements
with less frequent dosing [52]. Although the
frequency of dosing appeared to have a
significant impact on adherence in most cases,
efficacy and safety also remained an important
determinant of patient preference [83].
In a survey of 1,516 patients with type 2
diabetes, 46.8% reported that they would prefer
a once-weekly injectable medication rather
than a daily regimen; current injection users
were more than twice as likely to agree as
non-injection users (73.1% versus 31.5%;
P\0.001) [84].
Education and Intervention
A literature review of studies of older patients
with type 2 diabetes or cardiovascular disease
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found an inconsistent relationship between
adherence and health literacy, defined as a
patient’s ability to understand the information
needed to appropriately manage their disease
[85]. The authors concluded that measures to
improve health literacy may not necessarily
increase medication adherence. However,
diabetes self-management education is
regarded as essential for patients with type 2
diabetes [5, 18]. When adherence education
was added to pharmacotherapy for 172
patients with uncontrolled diabetes, mean
fasting blood glucose and HbA1c values of
patients in the intervention group decreased
significantly compared with those in the
control group (P\0.001) after 3 months [86].
However, data from a comprehensive
literature review suggested that such
interventions did not improve adherence if it
was already high [52].
Improving continuity of care (COC) for
patients with type 2 diabetes through better
patient–physician relationships and greater
information sharing has also been shown to be
associated with increased adherence and
improved outcomes [87]. For patients with a
high versus a low score for COC, the OR for
adherence (defined from MPR C80%) was 3.37
(95% CI 3.15–3.60). In a study of elderly
patients, the OR for receiving inappropriate
drugs was 0.44 (95% CI 0.43–0.45) for patients
with the highest versus the lowest COC, and the
OR for duplicated medication was 0.22 (95% CI
0.22–0.23) [88]. There was also a reduction in
likelihood of hospitalization, and the results
indicated that improved COC was associated
with a significant decrease in overall healthcare
expenditure.
In a randomized trial where patients received
up to 10 telephone calls from their health
educator at 4- to 6-week intervals over 1 year,
there was a significant improvement in
medication adherence for the patients who
were on OHAs. However, this intervention
was not effective in those patients taking
insulin [89]. Newer methods to increase
communication and relationships between
patients and healthcare providers are being
developed using resources such as electronic
medical records [90] and websites [91], and it is
anticipated that these will result in improved
medication adherence.
Co-payment and Adherence
For patients with diabetes, the average annual
costs per patient were shown in a study in Italy
to be lower for fixed-dose combination
therapies than either monotherapy or dual
therapies [92]. Similar to other therapeutic
areas, the cost of medications for diabetes
increases continually. One method of slowing
the rise in healthcare costs is to increase the
levels of co-payment by patients. A study in
Australia showed that when co-payments
under the pharmaceutical benefits scheme
increased by 24% in 2005, there was a
significant decrease in dispensing volumes of
various medications, including those for
diabetes and cardiovascular disease [93].
A United States study of levels of co-payment
for OHAs [94] showed a persistent reduction in
previously established OHA use when the
increased cost sharing was more than $10 per
30-day supply. Another United States study
demonstrated that a cost-sharing increase of
$10 was associated with a 5.4% decrease in
adherence to OHAs; the decreased adherence
was associated with an increase in diabetes-
related complications and resultant costs [95].
Conversely, a reduction in co-payment from
$15.3 to $10.1 for diabetes medications was
associated with increased adherence, from
75.3% to 82.6% [96].
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Financial incentives have been suggested
as a means of increasing compliance with
medications, although they are not
applicable to all patients [97]. Reducing co-
payments for statins in Medicare beneficiary
patients with diabetes was associated with
increased adherence and reduced medical
costs, particularly in high-risk cases [98].
Limiting the payments that patients are
required to make may increase adherence
and could reduce the overall long-term
costs.
CONCLUSION
It is evident from many studies that type 2
diabetes is a progressive disease and
pharmacologic treatment is essential to
maintain glycemic control and reduce adverse
cardiovascular outcomes. Even though
adherence to medications leads to beneficial
outcomes, it is often poor. There are numerous
reasons for poor adherence including age,
social and psychological factors, education
and a lack of understanding of the long-term
benefits of treatment, the complexity of the
medication regimen, cost of medication and
negative treatment perceptions. Poor
communication between doctor and patient,
adverse outcomes such as weight gain and
hypoglycemia, and failure of clinicians to
modify medications appropriately can also
affect adherence. New innovative methods are
needed to assist those patients who fail in their
medication compliance [54]. Measures to
increase patient satisfaction and counteract a
lack of adherence must be multifactorial;
strategies should include a reduction in the
complexity of the prescription regimen,
educational initiatives, improved doctor–
patient communication, reminder systems
and reduced costs.
BULLET-POINT SUMMARY
• Adherence to therapy is defined as the extent
to which a person’s behavior in taking
medication, following a diet, and/or
executing lifestyle changes, corresponds
with agreed recommendations from a
healthcare provider.
• Patients presenting with type 2 diabetes
mellitus are initially encouraged to maintain
a healthy diet and exercise regimen, followed
by early medication that generally includes
one or more oral antidiabetic drugs and later
may include an injectable treatment.
• Recommended glycemic goals are achieved
by less than 50% of patients, which may be
associated with reduced adherence to
therapies, and may lead to complications of
diabetes over time.
• Adherence to long-term exercise programs
can vary between 10% and 80%. Data from
different studies show that adherence to oral
hypoglycemic agents (OHA) ranged from
36% to 93% in patients remaining on
treatment for 6–24 months. In retrospective
insulin studies, adherence was 62% and 64%
for long-term and new-start insulin users,
respectively.
• Reasons for nonadherence to therapies
include age, information, perception and
duration of disease, complexity of dosing
regimen, polytherapy, psychological factors,
safety, tolerability and cost.
• Measures to increase therapy adherence in
type 2 diabetes include reducing complexity
by fixed-dose combinations and less
frequent dosing requirements, using
medications with improved safety profile,
educational initiatives, improved patient-
healthcare provider communication and
social support, which may help to reduce
costs.
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